{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:06:40Z","timestamp":1784045200962,"version":"3.55.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Timely treatment in colorectal cancer (CRC) may influence the disease course and, thus, outcomes, but optimal delay thresholds remain uncertain. Identifying pathway-specific time-to-treatment initiation (TTI) effects can guide benchmarks and policies for coordinated, timely care.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association between TTI and 3-year metastasis risk in patients with newly diagnosed nonmetastatic CRC undergoing curative-intent surgery, with attention to variation by treatment pathway.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study of insured US patients with nonmetastatic CRC used deidentified administrative claims from Optum\u2019s Clinformatics Data Mart. Eligible individuals were adults aged 40 years or older with incident nonmetastatic CRC diagnosed during January 1, 2017, to December 31, 2021, who underwent curative-intent surgery within 1 year of diagnosis and had continuous coverage 1 year before and after. Data were analyzed June 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n TTI was defined as days from CRC diagnosis to the first receipt of cancer-directed therapy (surgery, chemotherapy, or radiation). Patients were categorized into 4 treatment pathways: surgery with or without radiation, surgery followed by adjuvant therapy with or without radiation, neoadjuvant therapy followed by surgery with or without radiation, and trimodality therapy (neoadjuvant therapy, followed by surgery, followed by adjuvant therapy with or without radiation).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The outcome was 3-year cumulative incidence of metastasis. XGBoost identified optimal TTI thresholds, and Fine-Gray models with death as a competing risk evaluated these thresholds and estimated their associations with metastasis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 11\u202f927 patients (mean [SD] age, 70.7 [10.8] years; 6007 women [50.4%]; 1251 Black [10.5%], 7948 White [66.6%]), 4539 (38.0%) had moderate or severe comorbidity. Over 3 years, 1438 patients (12.1%) developed metastasis. Longer TTIs were associated with higher metastasis risk, varying by treatment pathway. For surgery plus adjuvant therapy, TTIs of 4 to 46 days (subdistribution hazard ratio [sHR], 1.27; 95% CI, 1.04-1.55) and 47 days or longer (sHR, 1.55; 95% CI, 1.08-2.23) were significantly associated with increased risk vs zero to 3 days. For surgery followed by radiation, delays of 223 days or longer showed higher risk (sHR, 2.00; 95% CI, 0.95-4.25) than TTI up to 222 days, although these results were not significant. For neoadjuvant therapy plus surgery, TTI of 68 days or longer were associated with higher risk (sHR, 2.66; 95% CI, 1.02-6.94) than TTI up to 67 days. For patients receiving trimodality therapy, there was no association between TTI and risk of metastasis.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, treatment delays were associated with higher, pathway-specific metastasis risk. These findings support pathway-tailored benchmarks for treatment initiation and highlight the importance of integrated care in reducing delays and improving timely, equitable, cost-effective CRC care.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.23057","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:30:17Z","timestamp":1784043017000},"page":"e2623057","source":"Crossref","is-referenced-by-count":0,"title":["Colorectal Cancer Treatment Delay Thresholds and Metastasis Risk"],"prefix":"10.1001","volume":"9","author":[{"given":"Chi M.","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Biostatistics & Health Data Science, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Skaar","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Imperiale","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis S.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics & Health Data Science, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick O.","family":"Monahan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics & Health Data Science, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita A.","family":"Turk","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai P.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Asia Pacific Research Center, Freeman Spogli Institute for International Studies, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"Suppl 1","key":"zoi260645r1","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1038\/bjc.2015.48","article-title":"Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review.","volume":"112","author":"Neal","year":"2015","journal-title":"Br J Cancer"},{"key":"zoi260645r2","doi-asserted-by":"publisher","first-page":"m4087","DOI":"10.1136\/bmj.m4087","article-title":"Mortality due to cancer treatment delay: systematic review and meta-analysis.","volume":"371","author":"Hanna","year":"2020","journal-title":"BMJ"},{"issue":"7","key":"zoi260645r4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: a review.","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"zoi260645r5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.21037\/jgo.2019.08.06","article-title":"Hepatic metastasis from colorectal cancer.","volume":"10","author":"Kow","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"zoi260645r6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jamcollsurg.2014.12.008","article-title":"Chemotherapy-induced splenic volume increase is independently associated with major complications after hepatic resection for metastatic colorectal cancer.","volume":"220","author":"Simpson","year":"2015","journal-title":"J Am Coll Surg"},{"issue":"13","key":"zoi260645r8","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer.","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi260645r9","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi260645r10","first-page":"20","article-title":"Late-stage diagnosis and cost of colorectal cancer treatment in two state Medicaid programs.","volume":"48","author":"Hoover","year":"2021","journal-title":"J Registry Manag"},{"issue":"1","key":"zoi260645r11","first-page":"52","article-title":"Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.","volume":"6","author":"Paramore","year":"2006","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"zoi260645r12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1186\/s12913-022-08457-6","article-title":"Increased healthcare costs by later stage cancer diagnosis.","volume":"22","author":"McGarvey","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"zoi260645r13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1080\/13696998.2023.2254649","article-title":"Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.","volume":"26","author":"McGarvey","year":"2023","journal-title":"J Med Econ"},{"issue":"4","key":"zoi260645r14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMp048143","article-title":"The price tag on progress\u2013chemotherapy for colorectal cancer.","volume":"351","author":"Schrag","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi260645r15","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1158\/2767-9764.CRC-25-0367","article-title":"Initial-care medical and prescription costs for incident metastatic versus nonmetastatic colorectal cancer.","volume":"5","author":"Nguyen","year":"2025","journal-title":"Cancer Res Commun"},{"issue":"8","key":"zoi260645r16","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.7150\/jca.71141","article-title":"Association between timing and duration of adjuvant chemotherapy and colorectal cancer survival in Korea, 2011-2014: a nationwide study based on the Health Insurance Review and Assessment Service Database.","volume":"13","author":"Choi","year":"2022","journal-title":"J Cancer"},{"issue":"12","key":"zoi260645r17","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.ejso.2015.09.009","article-title":"The impact of adjuvant chemotherapy timing on overall survival following colorectal cancer resection.","volume":"41","author":"Nachiappan","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"zoi260645r18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/cancers11040550","article-title":"Timing of adjuvant chemotherapy and survival in colorectal, gastric, and pancreatic cancer. a systematic review and meta-analysis.","volume":"11","author":"Petrelli","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"9","key":"zoi260645r19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/DCR.0000000000001762","article-title":"The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer.","volume":"63","author":"You","year":"2020","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"zoi260645r20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamasurg.2019.4551","article-title":"Review of the American Society of Colon and Rectal Surgeons clinical practice guidelines for the use of bowel preparation in elective colon and rectal surgery.","volume":"155","author":"Fry","year":"2020","journal-title":"JAMA Surg"},{"issue":"3","key":"zoi260645r22","first-page":"233","article-title":"Colorectal cancer statistics, 2023.","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"zoi260645r24","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO Guideline.","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260645r25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer.","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"25","key":"zoi260645r26","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1200\/JCO.22.01420","article-title":"FOLFOXIRI plus cetuximab or bevacizumab as first-line treatment of BRAFV600E-mutant metastatic colorectal cancer: the Randomized Phase II FIRE-4.5 (AIO KRK0116) Study.","volume":"41","author":"Stintzing","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi260645r27","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy.","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"issue":"3","key":"zoi260645r28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study.","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"issue":"12","key":"zoi260645r31","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality.","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"zoi260645r32","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"3","key":"zoi260645r33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon Cancer, version 2.2021, NCCN Clinical Practice Guidelines in Oncology.","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"zoi260645r34","doi-asserted-by":"publisher","first-page":"366","DOI":"10.6004\/jnccn.2024.0041","article-title":"NCCN Guidelines insights: rectal cancer, version 3.2024.","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi260645r36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"1","key":"zoi260645r38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210465","article-title":"Effect of length of time from diagnosis to treatment on colorectal cancer survival: a population-based study.","volume":"14","author":"Lee","year":"2019","journal-title":"PLoS One"},{"key":"zoi260645r39","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100036","article-title":"Impact of prior authorization on patient access to cancer care.","volume":"43","author":"Trapani","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"zoi260645r40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jnci\/djs502","article-title":"Tumor boards and the quality of cancer care.","volume":"105","author":"Keating","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"zoi260645r41","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1200\/JCO.2015.61.1558","article-title":"Association between geographic access to cancer care, insurance, and receipt of chemotherapy: geographic distribution of oncologists and travel distance.","volume":"33","author":"Lin","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi260645r42","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.cgh.2006.07.016","article-title":"Population-based analyses of lymph node metastases in colorectal cancer.","volume":"4","author":"Ricciardi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3-4","key":"zoi260645r43","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10555-012-9373-9","article-title":"The metastatic niche and stromal progression.","volume":"31","author":"Sleeman","year":"2012","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"zoi260645r44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.34065","article-title":"Development of a model to estimate the association between delay in cancer treatment and local tumor control and risk of metastases.","volume":"4","author":"Ng","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi260645r45","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s13304-024-01884-6","article-title":"Predicting lymph node metastasis in colorectal cancer patients: development and validation of a column chart model.","volume":"76","author":"Niu","year":"2024","journal-title":"Updates Surg"},{"issue":"1","key":"zoi260645r46","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000113","article-title":"Trends in wait time for colorectal cancer screening and diagnosis, 2013-2016.","volume":"11","author":"Hubers","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"14","key":"zoi260645r47","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1311194","article-title":"Multitarget stool DNA testing for colorectal-cancer screening.","volume":"370","author":"Imperiale","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi260645r48","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41571-020-0392-0","article-title":"ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.","volume":"17","author":"Dasari","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"zoi260645r49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ijc.34910","article-title":"Trends in management and outcomes of colon cancer in the United States over 15 years: analysis of the National Cancer Database.","volume":"155","author":"Horesh","year":"2024","journal-title":"Int J Cancer"},{"key":"zoi260645r30","volume-title":"Colorectal Cancer Guideline","author":"US Armed Forces Health Surveillance Division","year":"2022"},{"key":"zoi260645r3","unstructured":"American Society of Clinical Oncology. Colorectal cancer stages, 2022. Revised January 29, 2024. Accessed November 17, 2025. https:\/\/www.cancer.org\/cancer\/types\/colon-rectal-cancer\/detection-diagnosis-staging\/staged.html"},{"key":"zoi260645r7","unstructured":"American Cancer Society. Survival rates for colorectal cancer, 2024. Updated January 13, 2026. Accessed November 17, 2025. https:\/\/www.cancer.org\/cancer\/types\/colon-rectal-cancer\/detection-diagnosis-staging\/survival-rates.html"},{"key":"zoi260645r21","unstructured":"American Cancer Society. Colorectal cancer facts & figures 2023-2025. 2024. Accessed November 17, 2025. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/colorectal-cancer-facts-and-figures\/colorectal-cancer-facts-and-figures-2023.pdf"},{"key":"zoi260645r23","unstructured":"US Department of Health and Human Services. Guidance regarding methods for de-identification of protected health information in accordance with the Health Information Insurance Portability and Accountability Act (HIPAA) Privacy Rule. November 26, 2012. Accessed November 17, 2025. https:\/\/www.hhs.gov\/sites\/default\/files\/ocr\/privacy\/hipaa\/understanding\/coveredentities\/De-identification\/hhs_deid_guidance.pdf"},{"key":"zoi260645r29","unstructured":"US Armed Forces Health Surveillance Division. Surveillance case definitions. August 6, 2024. Accessed November 17, 2025. https:\/\/www.health.mil\/Military-Health-Topics\/Health-Readiness\/Public-Health\/AFHSD\/Epidemiology-and-Analysis\/Surveillance-Case-Definitions"},{"key":"zoi260645r35","unstructured":"Agency for Healthcare Research and Quality. Elixhauser comorbidity software refined for ICD-10-CM version 2024.1. December 2023. Accessed November 17, 2025. https:\/\/hcup-us.ahrq.gov\/toolssoftware\/comorbidityicd10\/CMR-User-Guide-v2024-1.pdf"},{"key":"zoi260645r37","doi-asserted-by":"crossref","unstructured":"Chen? T, Guestrin? C. XGBoost: a scalable tree boosting system. KDD\u201916 Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. Published online August 13, 2016. Accessed November 17, 2025. https:\/\/dl.acm.org\/doi\/10.1145\/2939672.2939785","DOI":"10.1145\/2939672.2939785"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851614\/nguyen_2026_oi_260645_1783451606.92403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:30:21Z","timestamp":1784043021000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.23057","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}